SLAMF6 deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint
SLAMF6 is a homotypic receptor of the Ig-superfamily whose exact role in immune modulation has remained elusive. Its constitutive expression on resting and activated T cells precludes it from being a bona fide exhaustion marker. By breeding Pmel-1 mice with SLAMF6 -/- mice, we generated donors for T...
| Published in: | eLife |
|---|---|
| Main Authors: | Emma Hajaj, Galit Eisenberg, Shiri Klein, Shoshana Frankenburg, Sharon Merims, Inna Ben David, Thomas Eisenhaure, Sarah E Henrickson, Alexandra Chloé Villani, Nir Hacohen, Nathalie Abudi, Rinat Abramovich, Jonathan E Cohen, Tamar Peretz, Andre Veillette, Michal Lotem |
| Format: | Article |
| Language: | English |
| Published: |
eLife Sciences Publications Ltd
2020-03-01
|
| Subjects: | |
| Online Access: | https://elifesciences.org/articles/52539 |
Similar Items
Alternative splicing of modulatory immune receptors in T lymphocytes: a newly identified and targetable mechanism for anticancer immunotherapy
by: Shay Tzaban, et al.
Published: (2025-01-01)
by: Shay Tzaban, et al.
Published: (2025-01-01)
Unveiling alternative splicing dynamics in activated T lymphocytes and their implications for immune checkpoint blockade efficacy
by: Elad Zisman, et al.
Published: (2025-05-01)
by: Elad Zisman, et al.
Published: (2025-05-01)
Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade
by: Michal Lotem, et al.
Published: (2016-01-01)
by: Michal Lotem, et al.
Published: (2016-01-01)
Negative regulation of humoral immunity due to interplay between the SLAMF1, SLAMF5, and SLAMF6 receptors
by: Ninghai eWang, et al.
Published: (2015-04-01)
by: Ninghai eWang, et al.
Published: (2015-04-01)
Role and Mechanism of SLAMF7-SLAMF7 Signaling Pathway in Tumor Progression
by: WANG Yuanyuan, et al.
Published: (2020-04-01)
by: WANG Yuanyuan, et al.
Published: (2020-04-01)
CRISPR-Mediated Triple Knockout of SLAMF1, SLAMF5 and SLAMF6 Supports Positive Signaling Roles in NKT Cell Development.
by: Bonnie Huang, et al.
Published: (2016-01-01)
by: Bonnie Huang, et al.
Published: (2016-01-01)
SLAMF7 and SLAMF8 receptors shape human plasmacytoid dendritic cell responses to intracellular bacteria
by: Joaquín Miguel Pellegrini, et al.
Published: (2025-09-01)
by: Joaquín Miguel Pellegrini, et al.
Published: (2025-09-01)
Corrigendum to SLAMF7 and SLAMF8 receptors shape human plasmacytoid dendritic cell responses to intracellular bacteria
by: Joaquín Miguel Pellegrini, et al.
Published: (2025-09-01)
by: Joaquín Miguel Pellegrini, et al.
Published: (2025-09-01)
The future of affordable cancer immunotherapy
by: Niels Schaft, et al.
Published: (2023-09-01)
by: Niels Schaft, et al.
Published: (2023-09-01)
Emerging roles of SLAMF7 in immune cells and related diseases
by: Zheng Zhang, et al.
Published: (2025-03-01)
by: Zheng Zhang, et al.
Published: (2025-03-01)
Slamf7 is dispensable in mouse models of acute lung injury
by: Emily M. King, et al.
Published: (2024-10-01)
by: Emily M. King, et al.
Published: (2024-10-01)
SLAMF7 defines subsets of human effector CD8 T cells
by: Hassen Kared, et al.
Published: (2024-12-01)
by: Hassen Kared, et al.
Published: (2024-12-01)
Expression and Significance of SLAMF7 in Intestinal Tissue and Intestinal Inflammation in Mice
by: YANG Yan, et al.
Published: (2024-02-01)
by: YANG Yan, et al.
Published: (2024-02-01)
Soluble SLAMF7 is generated by alternative splicing in multiple myeloma cells
by: Jiro Kikuchi, et al.
Published: (2024-06-01)
by: Jiro Kikuchi, et al.
Published: (2024-06-01)
Linking SLAMF1 to autophagy and sensitivity to therapy in chronic lymphocytic leukemia
by: Cinzia Bologna, et al.
Published: (2018-05-01)
by: Cinzia Bologna, et al.
Published: (2018-05-01)
SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments
by: Emily Chu, et al.
Published: (2023-08-01)
by: Emily Chu, et al.
Published: (2023-08-01)
SLAMF7 regulates the inflammatory response in macrophages during polymicrobial sepsis
by: Yongjian Wu, et al.
Published: (2023-03-01)
by: Yongjian Wu, et al.
Published: (2023-03-01)
Uncertainty of the perpetrator in killing and bodily harm
by: Abbas Shiri
Published: (2022-09-01)
by: Abbas Shiri
Published: (2022-09-01)
SLAMF1 expression in breast cancer cells delays tumor growth in vivo
by: Kyung-Hee Song, et al.
Published: (2025-08-01)
by: Kyung-Hee Song, et al.
Published: (2025-08-01)
A splice donor variant in SLAMF1 is associated with canine atopic dermatitis
by: Oliver P. Forman, et al.
Published: (2025-06-01)
by: Oliver P. Forman, et al.
Published: (2025-06-01)
Macrophage-T cell interactions promote SLAMF1 expression for enhanced TB defense
by: G. V. R. Krishna Prasad, et al.
Published: (2025-07-01)
by: G. V. R. Krishna Prasad, et al.
Published: (2025-07-01)
SLAMF receptors: key regulators of tumor progression and emerging targets for cancer immunotherapy
by: Jia Li, et al.
Published: (2025-05-01)
by: Jia Li, et al.
Published: (2025-05-01)
On Jensen-Related Inequalities for Various Types of Convexity via a Unified Approach
by: Shoshana Abramovich
Published: (2025-06-01)
by: Shoshana Abramovich
Published: (2025-06-01)
The immune receptor SLAMF5 regulates myeloid-cell mediated neuroinflammation in multiple sclerosis.
by: Laura Bellassen, et al.
Published: (2025-09-01)
by: Laura Bellassen, et al.
Published: (2025-09-01)
Correction: A splice donor variant in SLAMF1 is associated with canine atopic dermatitis
by: Frontiers Production Office
Published: (2025-08-01)
by: Frontiers Production Office
Published: (2025-08-01)
Clinical and immunological relevance of SLAMF6 expression in the tumor microenvironment of breast cancer and melanoma
by: Takaaki Oba, et al.
Published: (2024-01-01)
by: Takaaki Oba, et al.
Published: (2024-01-01)
Does cancer cell-expressed SLAMF7 impact on CD47-mediated phagocytosis?
by: Renee Bouwstra, et al.
Published: (2019-05-01)
by: Renee Bouwstra, et al.
Published: (2019-05-01)
SLAMF7 modulates B cells and adaptive immunity to regulate susceptibility to CNS autoimmunity
by: Patrick O’Connell, et al.
Published: (2022-10-01)
by: Patrick O’Connell, et al.
Published: (2022-10-01)
(Skew) Filters in Residuated Skew Lattices
by: R. Koohnavard, et al.
Published: (2018-06-01)
by: R. Koohnavard, et al.
Published: (2018-06-01)
SLAMF7 regulates goblet cell mucus production and negatively impacts gut homeostasis and commensalism
by: Dianrong Zhou, et al.
Published: (2025-12-01)
by: Dianrong Zhou, et al.
Published: (2025-12-01)
Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma
by: Roman Galetto, et al.
Published: (2024-07-01)
by: Roman Galetto, et al.
Published: (2024-07-01)
The prognostic and immune significance of SLAMF9 in pan-cancer and validation of its role in colorectal cancer
by: Chunmei Zhao, et al.
Published: (2024-08-01)
by: Chunmei Zhao, et al.
Published: (2024-08-01)
SLAMF8 promotes the proliferation and migration of synovial fibroblasts by regulating the ERK/MMPs signalling pathway
by: Jun Liu, et al.
Published: (2022-07-01)
by: Jun Liu, et al.
Published: (2022-07-01)
Skew-spectra and skew energy of various products of graphs
by: Xueliang Li, et al.
Published: (2015-06-01)
by: Xueliang Li, et al.
Published: (2015-06-01)
Steatohepatitis alters lymphocytes cytotoxicity and localization, accelerating colorectal liver metastases
by: Adi S. Yehezkel, et al.
Published: (2025-11-01)
by: Adi S. Yehezkel, et al.
Published: (2025-11-01)
Identification of methylation-related genes and the potential regulatory mechanism of SLAMF6 in CMS4 colorectal cancer
by: Huimin Liu, et al.
Published: (2025-10-01)
by: Huimin Liu, et al.
Published: (2025-10-01)
Evolutionary and structural basis of SLAMF1 utilization in morbilliviruses-Implications for host range and cross-species transmission.
by: Ayumu Hyodo, et al.
Published: (2025-06-01)
by: Ayumu Hyodo, et al.
Published: (2025-06-01)
Rescue SLAMF7 activity in exhausted natural killer cells: Novel challenges in the immunotherapy of multiple myeloma
by: Alessandra Zingoni, et al.
Published: (2022-12-01)
by: Alessandra Zingoni, et al.
Published: (2022-12-01)
P1025: A PILOT STUDY OF THE ANTI-SLAMF7 MONOCLONAL ANTIBODY, ELOTUZUMAB, IN PATIENTS WITH MYELOFIBROSIS.
by: Prithviraj Bose, et al.
Published: (2023-08-01)
by: Prithviraj Bose, et al.
Published: (2023-08-01)
ELOTUZUMAB FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA, WITH SPECIAL REFERENCE TO ITS MODES OF ACTION AND SLAMF7 SIGNALING
by: Masafumi Taniwaki, et al.
Published: (2018-02-01)
by: Masafumi Taniwaki, et al.
Published: (2018-02-01)
Similar Items
-
Alternative splicing of modulatory immune receptors in T lymphocytes: a newly identified and targetable mechanism for anticancer immunotherapy
by: Shay Tzaban, et al.
Published: (2025-01-01) -
Unveiling alternative splicing dynamics in activated T lymphocytes and their implications for immune checkpoint blockade efficacy
by: Elad Zisman, et al.
Published: (2025-05-01) -
Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade
by: Michal Lotem, et al.
Published: (2016-01-01) -
Negative regulation of humoral immunity due to interplay between the SLAMF1, SLAMF5, and SLAMF6 receptors
by: Ninghai eWang, et al.
Published: (2015-04-01) -
Role and Mechanism of SLAMF7-SLAMF7 Signaling Pathway in Tumor Progression
by: WANG Yuanyuan, et al.
Published: (2020-04-01)
